Thrombogenics Awarded €1.1 Million IWT Research Grant
News Feb 05, 2015
ThromboGenics NV has announced that it has been awarded a €1.1 million research grant from the Flemish agency for Innovation by Science and Technology (IWT).
The grant will be used by Thrombogenics to fund the on-going research to further elucidate the pharmacological effects ocriplasmin is exerting in the back of the eye following intravitreal (IVT) injection.
Dr Patrik De Haes, CEO of ThromboGenics comments: “The award of this grant from IWT supports our commitment to gain further insight into JETREA®s action in the vitreo-retinal interface. In conjunction with a growing body of real world and clinical trial data, we hope that the continual efforts at the preclinical research level will contribute to an improved awareness and acceptance of JETREA® by physicians as a first in class pharmaceutical treatment for symptomatic VMA.”
"Cell Quake Elastography" Maps Elasticity of Cell ComponentsNews
In somewhat the same way that seismologists use the vibrations of planet Earth to characterize its deep structure, scientists have discovered a way to use vibrations within cells to identify their mechanical properties.READ MORE
Diagnosing Immunity to Ebola With Paper Tests & SmartphonesNews
A promising new approach to detect immunity to Ebola virus infection has been developed by researchers from i-sense in a collaboration between UCL and Imperial College London.READ MORE